PTK2 (Protein Tyrosine Kinase 2) has traditionally been considered pro-oncogenic in many cancers, but recent evidence suggests context-dependent functions that may explain its association with improved survival in our cohort (Sulzmaier et al., 2014). The gene discussed is PTK2; the disease is cancer.